Abstract
Imatinib mesylate (STI 571, Gleevec) is a potent bcr-abl tyrosine kinase inhibitor. It also inhibits c-kit tyrosine kinase. Imatinib mesylate is active in the treatment of cronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It is considered by some authorities to be the standard of care in newly diagnosed CML as well as patients in chronic phase who do not have a related match. C-kit and its ligand stem-cell factor regulate melanocyte development and survival. Hypopigmentation in patients receiving imatinib mesylate for CML has been reported recently. In this article, we report a black Nigerian male with GIST, who developed hypopigmentation of distal parts of digits, as well as generalized lightening of skin on the body three months after receiving imatinib mesylate. We believe that this is the first case of hypopigmentation reported in a black patient with GIST.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Buchdunger E., Cioffi C. L., Law N., Stover D., Ohno-Jones S., Druker B. J., Lydon N. B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000 Oct;295(1):139–145. [PubMed] [Google Scholar]
- Etienne Gabriel, Cony-Makhoul Pascale, Mahon François-Xavier. Imatinib mesylate and gray hair. N Engl J Med. 2002 Aug 8;347(6):446–446. doi: 10.1056/NEJM200208083470614. [DOI] [PubMed] [Google Scholar]
- Fleischman R. A., Gallardo T., Mi X. Mutations in the ligand-binding domain of the kit receptor: an uncommon site in human piebaldism. J Invest Dermatol. 1996 Nov;107(5):703–706. doi: 10.1111/1523-1747.ep12365596. [DOI] [PubMed] [Google Scholar]
- Halaban R., Moellmann G. White mutants in mice shedding light on humans. J Invest Dermatol. 1993 Feb;100(2 Suppl):176S–185S. [PubMed] [Google Scholar]
- Raanani Pia, Goldman John M., Ben-Bassat Isaac. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol. 2002 Feb 1;20(3):869–870. doi: 10.1200/JCO.2002.20.3.869. [DOI] [PubMed] [Google Scholar]
- Spritz R. A. Molecular basis of human piebaldism. J Invest Dermatol. 1994 Nov;103(5 Suppl):137S–140S. doi: 10.1111/1523-1747.ep12399455. [DOI] [PubMed] [Google Scholar]
- Syrris P., Malik N. M., Murday V. A., Patton M. A., Carter N. D., Hughes H. E., Metcalfe K. Three novel mutations of the proto-oncogene KIT cause human piebaldism. Am J Med Genet. 2000 Nov 6;95(1):79–81. doi: 10.1002/1096-8628(20001106)95:1<79::aid-ajmg16>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]